Actos Bladder Cancer Lawsuit Claims
It has increasingly been reported that the drug Actos (pioglitazone), which is prescribed to treat diabetes, has been linked to an increased risk of developing bladder cancer for those who took the medicine for over one year. We are here to help people who have suffered from bladder cancer side effects after taking the medication Actos in filing Actos bladder cancer lawsuits.
In June 2011 the Food and Drug Administration (FDA) announced that patients who used the diabetes medicine Actos for longer than a year may have an elevated risk for developing bladder cancer. The Administration also required an Actos warning label change to reflect these findings. However, there is currently not an FDA Actos recall.
In its investigation of Actos’s safety, the FDA looked at data from a five year analysis of an ongoing epidemiological study. The FDA found that the longer patients took drugs containing pioglitazone, like Actos, the greater the risk of Actos causing bladder cancer. The same Actos and bladder cancer connection was also identified in patients with the highest cumulative dose of the drug.
FDA recommendations for healthcare professionals include not using pioglitazone (Actos) to treat patients who have been diagnosed with bladder cancer that is active and using the drug with patients who have had bladder cancer in the past only after weighing the benefits of the medication against the chance that the cancer will reoccur.
Actos, or pioglitazone, is manufactured by the Japanese pharmaceutical company Takeda to treat adults diagnosed with type 2 diabetes. Actos has been widely prescribed: in the first ten months in 2010, it is estimated that 2.3 million people filled a prescription from a retail pharmacy for medication containing pioglitazone.
Actos is available in several medication forms including:
• Actos (pioglitazone)
• Actoplus Met (pioglitazone/metformin)
• Actoplus Met XR (pioglitazone/metformin extended-release)
• Duetact (pioglitazone/glimepiride)
Actos And Bladder Cancer Lawsuit Help
If you took Actos and developed bladder cancer, please contact us. We represent all Actos lawsuit clients on a contingency basis which means that there are never any legal fees unless we win compensation in your case. For a free, no-obligation consultation please call toll free or fill out our short online contact form and an Actos and bladder cancer lawsuit lawyer will contact you to answer any of your questions including any future Actos recall news.
Featured Actos Bladder Cancer Lawsuit News
Takeda Pharmaceuticals, maker of the type II diabetes medication Actos, submitted data from an ongoing 10-year study examining the Actos and cancer risk link to the...
The FDA announced in June 2011 that using the medication for longer than one year may contribute to Actos causing bladder cancer.Takeda Pharmaceuticals, maker of the...
Actos was introduced to the U.S. market in 1999, and is prescribed to treat diabetes mellitus type 2. Recently there have been concerns regarding the link between Actos...
If you have diabetes and have been using the prescription medicine Actos, you may be concerned about recent studies linking Actos causing bladder cancer.
On June 15, 2011, the Food and Drug Administration updated their Actos bladder cancer FDA safety information on the type 2 diabetes medication Actos (brand...
Making a Difference
We believe that the manufacturer of Actos should be held accountable for any harm they are legally responsible for and patients should be fairly compensated for their damages due to a diagnosis of cancer… find out more
Requesting a free legal consultation does not create an attorney-client relationship and you are not considered a client until a representation agreement has been signed and your case has been accepted.
Worried that Actos Causes Bladder Cancer?
If you are taking Actos and are concerned about possible side effects, the FDA medication guide may be a good resource. All medications have risks, and your doctor can help you decide whether a medication will be good for you. find out more